Alla Katsnelson | Aug 1, 2009 | 7 min read
By Alla Katsnelson Adaptive Evolution A once-rare type of clinical trial that violates one of the sacred tenets of trial design is taking off, but is it worth the risk? Doriano Solinas When researchers at Pfizer first began a Phase 2 trial of an acute stroke therapy in 2000, they decided to take a novel approach. The study—called the ASTIN trial—would determine the drug’s optimal dose not with three or four diffe